Peculiarities of hemostasis in patients with COVID-19
- 作者: Kalinskaya A.1,2, Dukhin O.1,2, Molodtsov I.1, Anisimova A.2, Sokorev D.1, Elizarova A.1,2, Sapozhnikova O.1, Glebova K.1, Shakhidzhanov S.3, Spiridonov I.3, Ataullakhanov F.3,4, Shpektor A.2, Vasilieva E.1,2
-
隶属关系:
- Davydovsky City Clinical Hospital
- Yevdokimov Moscow State University of Medicine and Dentistry
- Center for Theoretical Problems of Physicochemical Pharmacology
- University of Pennsylvania
- 期: 卷 94, 编号 7 (2022)
- 页面: 876-883
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/109743
- DOI: https://doi.org/10.26442/00403660.2022.07.201754
- ID: 109743
如何引用文章
全文:
详细
Aim. Analysis of the dynamics of different stages of clot formation and its lysis in patients with different COVID-19 severity.
Materials and methods. We prospectively included 58 patients with COVID-19 (39 patients with moderate disease severity and 18 patients with severe disease) and 47 healthy volunteers as a control group. All participants underwent the assessment of flow-mediated dilation (FMD) of brachial artery, impedance aggregometry, rotational thromboelastometry and thrombodynamics. Von Willebrand factor antigen (vWF:Ag) quantification was also performed in patients with COVID-19. Measurements were repeated on the 3rd and 9th day of hospitalization.
Results. Compared to the control group, patients with COVID-19 showed reduced values of platelet aggregation and greater values of the clot growth rate, as well as its size and density. On the first day of hospitalization, we found no differences in the activity of plasma hemostasis and endogenous fibrinolysis between subgroups of patients. With the progression of the disease, the growth rate and size of the clot were higher in the severe subgroup, even despite higher doses of anticoagulants in this subgroup. An increase in platelet aggregation was noted during the progression of the disease, especially in the severe subgroup. There were no differences in the results of the FMD test by subgroups of patients. The vWF:Ag level was significantly higher in the severe subgroup.
Conclusion. Thus, plasma hemostasis followed by secondary platelet activation correlates with the severity of COVID-19. Patients with moderate to severe coronavirus infection have predominantly local rather than generalized endothelial dysfunction.
作者简介
Anna Kalinskaya
Davydovsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry
编辑信件的主要联系方式.
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0003-2316-4238
канд. мед. наук, зав. отд-нием неотложной кардиологии для больных с острым инфарктом миокарда; доц. каф. кардиологии
俄罗斯联邦, Moscow; MoscowOleg Dukhin
Davydovsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0003-2278-1154
врач-кардиолог; аспирант
俄罗斯联邦, Moscow; MoscowIvan Molodtsov
Davydovsky City Clinical Hospital
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0001-8154-9350
медицинский статистик
俄罗斯联邦, MoscowAleksandra Anisimova
Yevdokimov Moscow State University of Medicine and Dentistry
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0002-1215-132X
врач-ординатор
俄罗斯联邦, MoscowDenis Sokorev
Davydovsky City Clinical Hospital
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0003-4887-2185
врач-кардиолог
俄罗斯联邦, MoscowAntonina Elizarova
Davydovsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0001-8715-8916
врач-кардиолог; аспирант
俄罗斯联邦, Moscow; MoscowOlga Sapozhnikova
Davydovsky City Clinical Hospital
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0002-6520-5926
врач-кардиолог
俄罗斯联邦, MoscowKseniya Glebova
Davydovsky City Clinical Hospital
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0002-2559-9449
врач-кардиолог
俄罗斯联邦, MoscowSoslan Shakhidzhanov
Center for Theoretical Problems of Physicochemical Pharmacology
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0002-5677-8052
науч. сотр. лаб. биофизики
俄罗斯联邦, MoscowIlia Spiridonov
Center for Theoretical Problems of Physicochemical Pharmacology
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0001-7514-0559
вед. инженер отдела разработок
俄罗斯联邦, MoscowFazly Ataullakhanov
Center for Theoretical Problems of Physicochemical Pharmacology; University of Pennsylvania
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0003-3403-181X
канд. физ.-мат. наук, д-р биол. наук, проф., гл. науч. сотр.; приглашенный проф.
俄罗斯联邦, Moscow; Philadelphia, USAAlexander Shpektor
Yevdokimov Moscow State University of Medicine and Dentistry
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0001-6190-6808
чл.-кор. РАН, д-р мед. наук, проф., рук-ль Университетской клиники кардиологии
俄罗斯联邦, MoscowElena Vasilieva
Davydovsky City Clinical Hospital; Yevdokimov Moscow State University of Medicine and Dentistry
Email: kalinskaya.anna@gmail.com
ORCID iD: 0000-0002-6310-7636
д-р мед. наук, проф., глав. врач; рук-ль лаб. атеротромбоза
俄罗斯联邦, Moscow; Moscow参考
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
- Jenner WJ, Gorog DA. Incidence of thrombotic complications in COVID-19: On behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium. J Thromb Thrombolysis. 2021;52(4):999-1006. doi: 10.1007/s11239-021-02475-7
- Edler C, Schröder AS, Aepfelbacher M, et al. Dying with SARS-CoV-2 infection – an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med. 2020;134(4):1275-84. doi: 10.1007/s00414-020-02317-w
- McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021;3(3):e224-33. doi: 10.1016/S2665-9913(20)30420-3
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8. doi: 10.1056/NEJMoa2015432
- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
- O’Sullivan JM, Gonagle DM, Ward SE, et al. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. 2020;7(8):e553-5. doi: 10.1016/S2352-3026(20)30215-5
- Manne BK, Denorme F, Middleton EA, et al. Platelet Gene Expression and Function in COVID-19 Patients. Blood. 2020;136(11):1317-29. doi: 10.1182/blood.2020007214
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-73. doi: 10.1016/j.jacc.2020.04.031
- Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6. doi: 10.1111/jth.14810
- Калинская А.И., Саввинова П.П., Васильева Е.Ю., Шпектор А.В. Особенности тромбообразования и эндогенного фибринолиза у пациентов с острым коронарным синдромом. Российский кардиологический журнал. 2018;(9):12-6 [Kalinskaya AI, Savvinova PP, Vasilieva EYu, Shpektor AV. The specifics of clotting and endogenic fibrinolysis in acute coronary syndrome patients. Russian Journal of Cardiology. 2018;(9): 12-6 (in Russian)]. doi: 10.15829/1560-4071-2018-9-12-16
- Dukhin OA, Kalinskaya A, Uzhakhova H, et al. Clot formation and endogenous fibrinolysis in acs patients compared to patients with a history of st elevation myocardial infarction. Atherosclerosis. 2020;315:e233. doi: 10.1016/j.atherosclerosis.2020.10.733
- Rodriguez-Miguelez P, Seigler N, Harris RA. Ultrasound assessment of endothelial function: A technical guideline of the flow-mediated dilation test. J Vis Exp. 2016;(110):54011. doi: 10.3791/54011
- Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133-48. doi: 10.2147/VHRM.S44469
- Balandina AN, Serebriyskiy II, Poletaev AV, et al. Thrombodynamics – A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PLoS One. 2018;13(6):e0199900. doi: 10.1371/journal.pone.0199900
- Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res. 2014;133Suppl. 1(01):S21-4. doi: 10.1016/j.thromres.2014.03.012
- Yang J-R, Lo J, Ho Y-L, et al. Pandemic H1N1 and seasonal H3N2 influenza infection in the human population show different distributions of viral loads, which substantially affect the performance of rapid influenza tests. Virus Res. 2011;155(1):163-7. doi: 10.1016/j.virusres.2010.09.015
- Wang CC, Chang CT, Lin CL, et al. Hepatitis C virus infection associated with an increased risk of deep vein thrombosis: A population-based cohort study. Medicine (Baltimore). 2015;94(38):e1585. doi: 10.1097/MD.0000000000001585
- Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola Hemorrhagic Fever in Primate Models: Evidence that Hemorrhage Is Not a Direct Effect of Virus-Induced Cytolysis of Endothelial Cells. Am J Pathol. 2003;163(6):2371-82. doi: 10.1016/S0002-9440(10)63592-4
- Squizzato A, Gerdes VEA, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost. 2005;93(3):403-10. doi: 10.1160/TH04-08-0523
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-45. doi: 10.1016/S0140-6736(21)00676-0
- Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-42. doi: 10.1111/jth.14850
- Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135-40. doi: 10.1016/S1473-3099(20)30434-5
- Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46(6):1099-102. doi: 10.1007/s00134-020-06033-2
- Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389-91. doi: 10.1038/s41577-020-0343-0. Erratum in: Nat Rev Immunol. 2020.
- Goshua G, Pine AB, Meizlish ML, et al. Articles Endotheliopathy in COVID-19-associated coagulopathy : evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-82. doi: 10.1016/S2352-3026(20)30216-7
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8. doi: 10.1056/NEJMoa2015432
- Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19(2):513-21. doi: 10.1111/jth.15191
- Evans PC, Rainger GE, Mason JC, et al. Endothelial dysfunction in COVID-19: A position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020;116(14):2177-84. doi: 10.1093/cvr/cvaa230
- Ward SE, Curley GF, Lavin M, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192(4):714-9. doi: 10.1111/bjh.17273
- Shechter M, Shechter A, Koren-Morag N, et al. Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol. 2014;113(1):162-7. doi: 10.1016/j.amjcard.2013.08.051
- Vasilieva E, Vorobyeva I, Lebedeva A, et al. Brachial Artery Flow-mediated Dilation in Patients with Tako-Tsubo Cardiomyopathy. Am J Med. 2011;124(12):1176-9. doi: 10.1016/j.amjmed.2011.05.033
- Maruhashi T, Kajikawa M, Kishimoto S, et al. Diagnostic Criteria of Flow-Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin-Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery. J Am Heart Assoc. 2020;9(2):e013915. doi: 10.1161/JAHA.119.013915
- Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803-15. doi: 10.1038/nri2171
- Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-98. doi: 10.1007/s00134-020-06062-x
- Ladikou EE, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): Marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond). 2020;20(5):e178-82. doi: 10.7861/clinmed.2020-0346
- Philippe A, Chocron R, Gendron N, et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis. 2021;24(3):505-17. doi: 10.1007/s10456-020-09762-6
- Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136(11):1330-41. doi: 10.1182/blood.2020007252
- Abdi M, Hosseini Z, Shirjan F, et al. Effect of Aspirin on the prevention of pro-thrombotic states in hospitalized COVID-19 patients: Systematic review. Cardiovasc Hematol Agents Med Chem. 2022. doi: 10.2174/1871525720666220401102728
- Zareef R, Diab M, Al Saleh T, et al. Aspirin in COVID-19: Pros and Cons. Front Pharmacol. 2022;13:849628. doi: 10.3389/fphar.2022.849628
- RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143-51. doi: 10.1016/S0140-6736(21)01825-0
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. doi: 10.1111/jth.14768
- Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost. 2020;120(5):876-8. doi: 10.1055/s-0040-1709650